Arbutus Biopharma ( (ABUS) ) has released its Q2 earnings. Here is a breakdown of the information Arbutus Biopharma presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly chronic hepatitis B, using its proprietary RNA interference and PD-L1 inhibitor technologies. In its latest earnings report for the quarter ending June 30, 2025, Arbutus Biopharma highlighted a significant increase in revenue, driven primarily by collaborations and licenses, with total revenue reaching $10.7 million compared to $1.7 million in the same quarter last year. Key financial metrics revealed a net income of $2.5 million, a notable improvement from a net loss of $19.8 million in the previous year, attributed to reduced operating expenses and increased collaboration revenue. The company also reported a restructuring charge related to workforce reduction and the closure of its headquarters, which contributed to a decrease in operating expenses. Looking ahead, Arbutus Biopharma remains focused on advancing its clinical programs and defending its intellectual property, with management expressing confidence in its cash resources to support operations for the next 12 months.